Vascular Access
  U.S. Site
Indications & Warnings>>

The ProCol® Vascular Bioprosthesis has been approved by the U.S. Food and Drug Administration for the treatment of redo hemodialysis access patients. The product is not yet approved for first time access.

Hemodialysis Access

The ProCol® vascular bioprosthesis for hemodialysis access has been shown in clinical studies both in Europe and the United States to provide patients with end-stage renal disease with a viable alternative. The ProCol® bioprosthesis is a natural biological graft derived from a bovine mesenteric vein. The patented manufacturing and sterilization process ensures a product that is flexible, easy to suture and which exhibits physiologic pulsatile flow characteristics similar to a native fistula.

The graft may be implanted in a straight or loop configuration, according to the specific surgical need. The ProCol® has demonstrated clinical efficacy in the upper arm, forearm, and thigh.

Hemodialysis access grafts are available in 6 mm diameter and a variety of different lengths to meet individual patient requirements.

Soft and flexible, ProCol® is also cosmetically appealing from the patient's perspective, since the graft is less visible beneath the skin surface.

The pulsatility of the graft provides peace of mind for the patient by providing an indication of flow and patency

ProCol® is highly biocompatible and elicits no antibody reactions

In U.S. clinical studies the ProCol ® bioprosthesis demonstrated improved patency compared with ePTFE grafts. ProCol ® succeeded where others had failed, with some patients ProCol ® grafts still patent after 5 years.

The ProCol® Bioprosthesis is stored in sterile saline, so preparation in the operating room is easily accomplished via a simple, quick rinsing process

The ProCol® may be accessed for hemodialysis as soon as two weeks following implant, based upon the physician's decision and patient tolerance

Handling and suturing characteristics are similar to the patient's native tissue making it easy to work with during the implant procedure.

The natural tissue is easily punctured in the hemodialysis setting - affording the ease of access associated with a native fistula. Hemostasis is also readily achieved with minimal pressure following the removal of the hemodialysis needles.


Highly elastic and compliant ProCol® is capable of handling high flow rates



Home | About Us | Products | Medical Professionals
News & Events | Careers | Links | Contact Us | Legal Disclaimers

Copyright© 2004 by Hancock Jaffe Laboratories, Inc. All Rights Reserved